<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272374</url>
  </required_header>
  <id_info>
    <org_study_id>CZHKI-HDVA-004</org_study_id>
    <nct_id>NCT02272374</nct_id>
  </id_info>
  <brief_title>Vascular Access Choice and Outcomes in the Elderly and Very Elderly With End Stage Renal Disease in China</brief_title>
  <acronym>ACCESS-China</acronym>
  <official_title>Vascular Access Choice and Outcomes in the Elderly and Very Elderly With End Stage Renal Disease in China :a Multicenter Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Haidian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the clinical outcomes and cost-effectiveness of
      different vascular access(arteriovenous fistula, tunneled cuffed catheter and arteriovenous
      graft) in the elderly and very elderly with end-stage renal disease in China.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The patency rate of vascular access</measure>
    <time_frame>2 years</time_frame>
    <description>Including primary and secondary patency rate.Blood flow can be above 500 mL/min in a mature arteriovenous fistula by ultrasound scan and 4 times of body weight (Kg*4 mL/min) in a arteriovenous graft or tunneled cuffed catheter in dialysis practice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of vascular access construction on ventricular volumes and left ventricular remodeling</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by doppler echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of vascular access construction on brain MRI and cognitive functionslesions and cognitive function</measure>
    <time_frame>2 years</time_frame>
    <description>Cognitive functions are assessed by psychic and autonomy scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications of vascular access</measure>
    <time_frame>2 years</time_frame>
    <description>Described as %.Complications including bleeding, infection, thrombosis, artery steal syndrome, heart failure, inadequate dialysis, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of different vascular access</measure>
    <time_frame>2 years</time_frame>
    <description>Described as $.The cost including medical expenses and non-medical expenses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate due to vascular access.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to vascular access</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>e-AVF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 elderly with end stage renal disease will undergo AVF creation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>e-TCC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 elderly with end stage renal disease will undergo TCC placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>e-AVG group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 elderly with end stage renal disease will undergo AVG creation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ve-AVF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 very elderly with end stage renal disease will undergo AVF creation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ve-TCC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 very elderly with end stage renal disease will undergo TCC placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ve-AVG group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 very elderly with end stage renal disease will undergo AVG creation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AVF creation</intervention_name>
    <arm_group_label>e-AVF group</arm_group_label>
    <arm_group_label>ve-AVF group</arm_group_label>
    <other_name>Arteriovenous fistula creation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TCC placement</intervention_name>
    <arm_group_label>e-TCC group</arm_group_label>
    <arm_group_label>ve-TCC group</arm_group_label>
    <other_name>Tunneled cuffed catheter placement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AVG creation</intervention_name>
    <arm_group_label>e-AVG group</arm_group_label>
    <arm_group_label>ve-AVG group</arm_group_label>
    <other_name>Arteriovenous graft creation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The elderly and very elderly with end stage renal disease.

          2. Estimated glomerular filtration rate (eGFR) &lt;20ml/min*1.73m2

          3. All study subjects agree to participate in the study and provide written informed
             consent.

        Exclusion Criteria:

          1. Patients' life expectancy is less than 2 years.

          2. Mental illness that makes the patients unable to complete the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changlin Mei, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Shanghai ChangZheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohong Hu, master</last_name>
    <phone>+8615026520819</phone>
    <email>huxiaohong8305@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Changlin Mei</investigator_full_name>
    <investigator_title>Professor, Director, Division of Nephrology</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Arteriovenous fistula</keyword>
  <keyword>Tunneled cuffed catheter</keyword>
  <keyword>Arteriovenous graft</keyword>
  <keyword>Elderly</keyword>
  <keyword>Very elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

